Kudo, MasatoshiMasatoshiKudoFinn, Richard SRichard SFinnANN-LII CHENGZhu, Andrew XAndrew XZhuDucreux, MichelMichelDucreuxGalle, Peter RPeter RGalleSakamoto, NaoyaNaoyaSakamotoKato, NaoyaNaoyaKatoNakano, MichitakaMichitakaNakanoJia, JingJingJiaVogel, ArndtArndtVogel2024-02-052024-02-052023-102235-1795https://scholars.lib.ntu.edu.tw/handle/123456789/639592Atezolizumab + bevacizumab showed survival benefit in patients with unresectable hepatocellular carcinoma (HCC) versus sorafenib in the Phase III IMbrave150 study. This exploratory analysis examined the prognostic impact of a baseline albumin-bilirubin (ALBI) score.enAlbumin-bilirubin grade; Atezolizumab; Bevacizumab; Unresectable hepatocellular carcinoma[SDGs]SDG3Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Studyjournal article10.1159/000529996379017662-s2.0-85175167269https://api.elsevier.com/content/abstract/scopus_id/85175167269